Different mechanisms involved in liraglutide and glucagon‐like peptide‐1 vasodilatation in rat mesenteric small arteries

Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years

(2017) Thomas Danne et al.   JOURNAL OF PEDIATRICS

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries

(2016) Cecilie Egholm et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

(2016) Mark M. Smits et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice

(2016) Sebastian Steven et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Cardiovascular Biology of Glucagon-like Peptide-1

(2016) Daniel J. Drucker   Cell Metabolism

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Experimental design and analysis and their reporting: new guidance for publication in BJP

(2015) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP

(2015) John C McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

(2015) Juraj Koska et al.   DIABETES

Risk of cardiovascular disease: The effects of diabetes and anti-diabetic drugs — A nested case–control study

(2015) Michael Gejl et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

(2015) Melanie J. Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose

(2015) S.M. Salheen et al.   PHARMACOLOGICAL RESEARCH

Cardiovascular Actions of Incretin-Based Therapies

(2014) John R. Ussher et al.   CIRCULATION RESEARCH

The effect of liraglutide on endothelial function in patients with type 2 diabetes

(2014) Debashis Nandy et al.   Diabetes & Vascular Disease Research

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities

(2014) Asger Lund et al.   European Journal of Internal Medicine

Effects of Glucagon-like Peptide-1 in Diabetic Rat Small Resistance Arteries

(2014) Zeliha Bayram et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials

(2014) Vivian A. Fonseca et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model

(2013) P. Richards et al.   DIABETES

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice

(2012) Naim Panjwani et al.   ENDOCRINOLOGY

The Glucagon-Like Peptide-1 Receptor—or Not?

(2012) Charles Pyke et al.   ENDOCRINOLOGY

Exenatide Alters Myocardial Glucose Transport and Uptake Depending on Insulin Resistance and Increases Myocardial Blood Flow in Patients with Type 2 Diabetes

(2012) M. Gejl et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fiji: an open-source platform for biological-image analysis

(2012) Johannes Schindelin et al.   NATURE METHODS

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase–Mediated, Nitric Oxide–Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy

(2010) Siva Bhashyam et al.   Circulation-Heart Failure

Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes

(2010) J. Koska et al.   DIABETES CARE

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP

(2008) Brian D. Green et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries

(2008) U Simonsen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Elevated pressure selectively blunts flow-evoked vasodilatation in rat mesenteric small arteries

(2006) F H Christensen et al.   BRITISH JOURNAL OF PHARMACOLOGY